Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease.

NCT07257185 is registered in ClinicalTrials.gov with Minghui Pharmaceutical (Hangzhou) Ltd as lead sponsor.

NCT NCT07257185
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07257185 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of MHB018A Injection in Subjects With Chronic Moderate-to-Severe Thyroid Eye Disease.
Lead sponsor
Minghui Pharmaceutical (Hangzhou) Ltd
Phase
Phase 3
Overall status
Active, not recruiting
Start date
March 17, 2026
Completion date
August 31, 2028
Enrollment
150 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid eye disease (ted)